Actively Recruiting
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Led by AstraZeneca · Updated on 2026-03-02
72
Participants Needed
21
Research Sites
154 weeks
Total Duration
On this page
Sponsors
A
AstraZeneca
Lead Sponsor
P
Parexel
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
CONDITIONS
Official Title
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with relapsed or refractory MDS or dysplastic CMML with peripheral or bone marrow blasts less than 20%, having received one or more prior lines of therapy.
- Histologically confirmed diagnosis based on WHO 2016 classification of myeloid neoplasms.
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.
- Symptomatic disease requiring therapy and allowing objective efficacy assessments.
- Willingness to provide baseline bone marrow aspirate or biopsy if needed.
- Use of contraception consistent with local regulations and study protocol.
- Women of childbearing potential must have a negative serum pregnancy test at screening.
You will not qualify if you...
- Prior treatment with IRAK inhibitors or inflammasome pathway inhibitors.
- Antineoplastic therapy (except hydroxyurea) within 15 days before first dose.
- Use of strong or moderate CYP3A inhibitors within 15 days before first dose.
- Major surgery within 28 days before first dose or not fully recovered from surgery.
- Use of drugs that prolong QT interval or risk Torsades de Pointes within 15 days before first dose.
- Immunosuppressive medications within 28 days before first dose, or systemic steroids over 10 mg/day prednisone equivalent within 15 days.
- Live attenuated vaccines within 28 days before first dose.
- Active major bleeding event.
- Any systemic disease, significant clinical disorder, or lab abnormality making study participation undesirable.
- Mean resting corrected QT interval (QTcF) over 450 ms (470 ms if bundle branch block) on ECG.
- History of intracranial bleeding within 6 months before first dose.
- Active gastrointestinal disease or condition interfering with oral therapy absorption.
- History of prior non-haematologic cancer (with some exceptions).
- Unresolved Grade over 2 toxicities from prior anticancer therapies (with some exceptions).
- Concurrent enrollment in another clinical study (with some exceptions).
- Known hypersensitivity to study drug or its components.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Research Site
Miami, Florida, United States, 33136
Not Yet Recruiting
2
Research Site
Tampa, Florida, United States, 33612
Actively Recruiting
3
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
4
Research Site
Heidelberg, Australia, 3084
Actively Recruiting
5
Research Site
Melbourne, Australia, 3000
Actively Recruiting
6
Research Site
Shinagawa-ku, Japan, 141-0022
Actively Recruiting
7
Research Site
Yoshida-gun, Japan, 910-1193
Actively Recruiting
8
Research Site
Seoul, South Korea, 05505
Withdrawn
9
Research Site
Seoul, South Korea, 3722
Withdrawn
10
Research Site
Barcelona, Spain, 08035
Actively Recruiting
11
Research Site
Madrid, Spain, 28027
Actively Recruiting
12
Research Site
Madrid, Spain, 28033
Actively Recruiting
13
Research Site
Pamplona, Spain, 31008
Actively Recruiting
14
Research Site
Salamanca, Spain, 37007
Actively Recruiting
15
Research Site
Valencia, Spain, 46026
Withdrawn
16
Research Site
Kaohsiung City, Taiwan, 83301
Not Yet Recruiting
17
Research Site
Tainan, Taiwan, 70403
Not Yet Recruiting
18
Research Site
Taipei, Taiwan, 100
Actively Recruiting
19
Research Site
London, United Kingdom, SE5 9RS
Actively Recruiting
20
Research Site
London, United Kingdom, W1T 7HA
Actively Recruiting
21
Research Site
Manchester, United Kingdom, M20 4BX
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here